Aminocaproic Acid
FDA-approved product (tablet, oral), marketed as Amicar, Aminocaproic, Aminocaproic Acid and 1 more.
- Registered studies
- 36
- Lab records
- 0
- Pathogens at ≥40%
- 0 of 4
Chemical structure
Existing / approved use
Documented · FDA, WHO, ChEMBL- WHO therapeutic group
- Amino acids
- FDA pharmacologic class
- Antifibrinolytic Agent FDA label ↗
- Anti-infective classification
- Not classified as an anti-infective.
Repurposing investigation
No supported pathogen reaches ≥40% AI-predicted activity for Aminocaproic Acid, so it is not among the repurposing candidates. Its predictions are shown below.
AI-predicted activity
AI prediction · nothing measured- MRSA17.1% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- E. coli8.1% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- K. pneumoniae19.1% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- M. tuberculosis15.0% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.
Evidence
Clinical and experimental
Documented evidenceClinical
36registered studies name this medicine, for any condition. See them below.
Experimental
No evidence found
No laboratory measurement against the four pathogens in the ChEMBL records loaded here.
Docking
Computational · nothing measuredDihydrofolate reductase ↗ (E. coli)
Not yet docked: queued in the docking rundetails
KPC-2 carbapenemase ↗ (K. pneumoniae)
Not yet docked: queued in the docking rundetails
Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)
Not yet docked: queued in the docking rundetails
Dihydrofolate reductase ↗ (MRSA)
Not yet docked: queued in the docking rundetails
AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.
Other medicines to investigate
AI prediction · nothing measuredOther repurposing candidates: approved medicines besides Aminocaproic Acid with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.
Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.
- UrsodiolExisting use: Biliary liver cirrhosis, Primary biliary cirrhosis69.2% AI-predicted activityagainst MRSA50+ registered studies
- OlaparibExisting use: Breast cancer, Breast carcinoma, Breast neoplasm and 9 more69.2% AI-predicted activityagainst MRSA50+ registered studies
- Ganirelix AcetateExisting use: Female infertility, Positive regulation of ovulation, Reproductive Techniques, Assisted69.1% AI-predicted activityagainst MRSA50+ registered studies
- DanicopanExisting use: Acquired paroxysmal nocturnal hemoglobinuria, Hemoglobinuria, Paroxysmal, Hemolysis68.7% AI-predicted activityagainst MRSA30 registered studies
- Simeprevir SodiumExisting use: Chronic hepatitis C virus infection68.6% AI-predicted activityagainst MRSANo documented evidence found
- Lanreotide AcetateExisting use: Acromegaly, Carcinoid syndrome68.3% AI-predicted activityagainst MRSA50+ registered studies
- Cholic AcidExisting use: Abnormality of the gastrointestinal tract, Inborn errors of metabolism, Liver disease and 1 more68.0% AI-predicted activityagainst MRSA50+ registered studies
- EptifibatideExisting use: Acute coronary syndrome, Acute myocardial infarction, Intermediate coronary syndrome and 2 more67.8% AI-predicted activityagainst MRSA35 registered studies
- AbarelixExisting use: Neoplasm67.7% AI-predicted activityagainst MRSA5 registered studies
- EverolimusExisting use: Adenoma sebaceum, Anaplastic astrocytoma, Angiomyolipoma and 18 more67.5% AI-predicted activityagainst MRSA50+ registered studies
- Paliperidone PalmitateExisting use: Mental or behavioural disorder, Psychosis, Schizoaffective disorder and 1 more67.3% AI-predicted activityagainst MRSA50+ registered studies
- PaliperidoneExisting use: Mental or behavioural disorder, Psychosis, Schizoaffective disorder and 1 more67.2% AI-predicted activityagainst MRSA50+ registered studies
Registered studies
A registration describes a study; it does not establish a positive result.
Tranexamic Acid (TXA) Versus Epsilon Aminocaproic Acid (EACA) Versus Placebo for Spine Surgery
NCT00958581 · start 2008-12
Registered record
- Registry ID
- NCT00958581
- Conditions
- Scoliosis
- Interventions
- Tranexamic Acid; Normal Saline; Epsilon aminocaproic acid
- Study type
- INTERVENTIONAL
- Phase
- Phase 4
- Registry status
- Completed
- Start
- 2008-12
- Completion
- 2012-09
- Enrolment
- 177
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionScoliosisInterventionTranexamic Acid; Normal Saline; Epsilon aminocaproic acidPhasePhase 4Registry statusCompletedEfficacy of Tranexamic Acid and Epsilon-aminocaproic Acid in Reducing Bleeding and Transfusions in Cardiac Surgery
NCT02655653 · start 2008-10
Registered record
- Registry ID
- NCT02655653
- Conditions
- Bleeding
- Interventions
- Epsilon-aminocaproic acid administered; Tranexamic Acid administered
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 2008-10
- Completion
- 2015-10
- Enrolment
- 114
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionBleedingInterventionEpsilon-aminocaproic acid administered; Tranexamic Acid administeredPhasePhase 3Registry statusCompletedEffects of Aprotinin During Cardiac Surgery/Long Term Death Rates
NCT00617955 · start 2007-09
Registered record
- Registry ID
- NCT00617955
- Conditions
- Cardiac Surgery
- Interventions
- Aprotinin; Amicar
- Study type
- OBSERVATIONAL
- Phase
- Not recorded
- Registry status
- Completed
- Start
- 2007-09
- Completion
- 2009-06
- Enrolment
- 462
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionCardiac SurgeryInterventionAprotinin; AmicarPhaseNot recordedRegistry statusCompletedBradykinin Receptor Antagonism During Cardiopulmonary Bypass
NCT00223704 · start 2006-05
Registered record
- Registry ID
- NCT00223704
- Conditions
- Cardiopulmonary Bypass; Inflammation; Fibrinolysis; Surgery
- Interventions
- HOE 140; Aminocaproic Acid; Placebo
- Study type
- INTERVENTIONAL
- Phase
- Phase 2 / Phase 3
- Registry status
- Completed
- Start
- 2006-05
- Completion
- 2012-06
- Enrolment
- 150
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionCardiopulmonary Bypass; Inflammation; Fibrinolysis; SurgeryInterventionHOE 140; Aminocaproic Acid; PlaceboPhasePhase 2 / Phase 3Registry statusCompletedPlatelet Function And Aggregometry In Patients With Aortic Valve Stenosis
NCT00156520 · start 2005-03
Registered record
- Registry ID
- NCT00156520
- Conditions
- Hemorrhage
- Interventions
- aprotonin; epsilon aminocaproic acid
- Study type
- INTERVENTIONAL
- Phase
- Phase 4
- Registry status
- Completed
- Start
- 2005-03
- Completion
- 2005-09
- Enrolment
- 40
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHemorrhageInterventionaprotonin; epsilon aminocaproic acidPhasePhase 4Registry statusCompletedEpsilon-Aminocaproaic Acid to Reduce the Need for Blood Transfusions During and Following Spine Surgery
NCT00320619 · start 2000-09
Registered record
- Registry ID
- NCT00320619
- Conditions
- Scoliosis; Kyphosis; Lordosis; Spondylitis; Spinal Stenosis
- Interventions
- Epsilon-Aminocaproic Acid (EACA); Placebo
- Study type
- INTERVENTIONAL
- Phase
- Not applicable
- Registry status
- Completed
- Start
- 2000-09
- Completion
- 2006-02
- Enrolment
- 182
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionScoliosis; Kyphosis; Lordosis; Spondylitis +1 moreInterventionEpsilon-Aminocaproic Acid (EACA); PlaceboPhaseNot applicableRegistry statusCompleted